W
WAVEMAN · COMPANY
HUN · Huntsman Corp
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

HUN

Huntsman CORP
PHARMA & BIOTECH · CHEMICALS & ALLIED PRODUCTS · CIK 0001307954
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$981.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
170
13F, latest reported quarter
REVENUE GROWTH
-5.8%
XBRL, annual
NET MARGIN
-5.0%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$981.0K over 180 days
+$981.0K over 90 days
more than 88% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
170 funds added or opened last quarter
more than 82% of Pharma & Biotech
REVENUE
-5.8% year over year
below 66% of Pharma & Biotech
MARGIN
-5.0% net margin
more than 60% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
9.0% of shares outstanding short · 3.9 days to cover · settled 2026-07-31
more than 73% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
170 funds added or opened positions in the latest 13F quarter, of 360 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -8.7%
-8.7%12M
-31%-4%+24%+51%2025-092025-102025-122026-032026-052026-072026-09 2026-08-03 · Huntsman Peter R bought $981.0K2025-11-10 · Lister Philip M. bought $242.9K2026-02-20 · Peter R. Huntsman filed a 5%+ stake (5.09%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $981.0K bought by insiders over 180 days, 170 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Huntsman CORP insiders bought a net $981.0K of stock across 12 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Huntsman Peter R
Chairman, President & CEO
BUY
2026-08-03
100,000.0
$981.0K
Lister Philip M.
Exec VP & CFO
BUY
2025-11-10
29,762.0
$242.9K
Huntsman Peter R
Chairman, President & CEO
BUY
2025-05-07
23,000.0
$257.6K
Huntsman Peter R
Chairman, President & CEO
BUY
2025-05-07
22,000.0
$245.7K
Huntsman Peter R
Chairman, President & CEO
BUY
2025-05-05
42,000.0
$493.1K
12 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 7 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
18,243,856.0 sh
$193.7M
VANGUARD PORTFOLIO MANAGEMENT LLC
9,166,098.0 sh
$97.3M
AQR CAPITAL MANAGEMENT LLC
8,713,741.0 sh
$92.5M
AMERICAN CENTURY COMPANIES INC
7,594,395.0 sh
$80.7M
VANGUARD CAPITAL MANAGEMENT LLC
7,514,930.0 sh
$79.8M
5%+ owners
13D = intent to influence · 13G = passive
Peter R. Huntsman
ACTIVIST 13D · 2026-02-20
5.09%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
WPG Partners Select Small Cap Value Fund
$4.0M POSITION · AS OF 2026-02-28
1.9%
Pzena Mid Cap Value Fund
$1.8M POSITION · AS OF 2026-02-28
1.8%
First Trust Materials AlphaDEX Fund
$6.6M POSITION · AS OF 2026-04-30
1.7%
Pzena Small Cap Value Fund
$1.6M POSITION · AS OF 2026-02-28
1.7%
Guardian Small Cap Value Diversified VIP Fund
$2.4M POSITION · AS OF 2026-03-31
1.6%
ICON EQUITY INCOME FUND
$653.5K POSITION · AS OF 2026-03-31
1.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Peter R. Huntsman
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$15.2M
$5.7M
$2.9M
+18%
+12%
2022
$13.4M
$9.7M
$3.2M
+24%
-4%
2021
$14.1M
$28.4M
$3.3M
+53%
+18%
2020
$13.5M
$12.3M
$3.0M
+8%
+8%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$5.7B$6.0B$6.1B$8.0B
GROSS PROFIT$751.0M$866.0M$906.0M$1.5B
OPERATING INCOME$-131.0M$-25.0M$84.0M$672.0M
NET INCOME$-284.0M$-189.0M$101.0M$460.0M
EPS (DILUTED)-1.65-1.100.572.27
OPERATING CASH FLOW$289.0M$263.0M$209.0M$914.0M
CASH$429.0M$340.0M$540.0M$654.0M
LONG-TERM DEBT$1.7B$1.5B$1.7B$1.7B
BUYBACKS$0$4.0M$349.0M$1.0B
DIVIDENDS PAID$146.0M$174.0M$169.0M$171.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →